María Dolores López-Fernández

María Dolores López-Fernández

Auto-generated profile, based on publicly available information

María Dolores López-Fernández

Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2023 in European Journal of Oncology Nursing
Verified
Journal Article
Closed access
CMCelia Martínez-Guijarro
Celia Martínez-Guijarro
MLMaría Dolores López-Fernández
María Dolores López-Fernández
MLMaria Lopez-Garzon
Maria Lopez-Garzon
MLMario Lozano-Lozano
Mario Lozano-Lozano
MAManuel Arroyo-Morales
Manuel Arroyo-Morales
NGNoelia Galiano-Castillo
Noelia Galiano-Castillo

17 February 2024 in Supportive Care in Cancer
Verified
Journal Article
Open access
PDF file
MLMaría Dolores López-Fernández
María Dolores López-Fernández
Carolina Fernández LaoCarolina Fernández Lao
Carolina Fernández Lao
ARAlba María Ruíz-Martínez
Alba María Ruíz-Martínez
MFMiguel Ángel Fernández-Gualda
Miguel Ángel Fernández-Gualda
Mario LozanoMario Lozano
Mario Lozano
Noelia Galiano CastilloNoelia Galiano Castillo
Noelia Galiano Castillo
Purpose: To evaluate the prevalence of dysphagia in survivors of head and neck cancer (sHNC) and to identify the predictors contributing to the development of dysphagia. Methods: We enrolled 62 sHNC in a cross-sectional study to check the prevalence of dysphagia in sHNC and to evaluate which factors were influencing the presence of this side effect. Besides dysphagia, sociodemographic and clinical characteristics, oral symptoms, maximal mouth opening (MMO), sleep quality and physical condition were evaluated, and a linear regression analysis was performed to verify which of these outcomes impact dysphagia. Results: Among all the sHNC, 85.5% presented dysphagia. The linear regression analysis confirmed that 44.9% of the variance in dysphagia was determined by coughing, MMO and sleep quality, being MMO the most powerful predictor, followed by coughing and sleep quality. Conclusion: Dysphagia affected the great majority of sHNC. Moreover, symptoms as coughing, reduced MMO and sleep disorders may act as predictors contributing to the development of dysphagia. Our results emphasize the importance of an early and proper identification of the symptoms as well as an adequate treatment strategy to address the cluster of symptoms that sHNC undergo.

24 January 2024 in BMJ Open
Verified
Journal Article
Open access
PDF file
MLMaria Lopez-Garzon
Maria Lopez-Garzon
MLMaría Dolores López-Fernández
María Dolores López-Fernández
ARAlba Maria Ruíz-Martínez
Alba Maria Ruíz-Martínez
PGPilar Galván-Banqueri
Pilar Galván-Banqueri
Mario LozanoMario Lozano
Mario Lozano
Noelia Galiano CastilloNoelia Galiano Castillo
Noelia Galiano Castillo
Introduction: The role of photobiomodulation (PBM) therapy for oral tissue damage induced by cancer treatment is currently unclear, and there is low-quality to moderate-quality evidence supporting the use of this approach for treating xerostomia and/or hyposalivation. Consequently, patients with head and neck cancer increasingly turn to basic oral hygiene to alleviate salivary gland dysfunction, and their adherence can be improved by mobile health (mHealth) education. The primary objective of this study will be to analyse the effects of different doses of PBM therapy (7.5 J/cm2 vs 3 J/cm2) plus mHealth education on quality of life (QoL), oral health, salivary secretion and salivary gland ultrasound assessment at postintervention and at the 6-month follow-up in patients with head and neck cancer after radiotherapy compared with those in control group. Methods and analysis: A prospective, three-arm, randomised, placebo-controlled, double-blinded study will be conducted among patients with head and neck cancer suffering from chronic xerostomia. A total of 20 patients per arm will be included and randomly assigned to receive 7.5 J/cm2 of PBM, 3 J/cm2 of PBM or placebo therapy. PBM therapy will be applied during 24 sessions at 22 points extra and intraorally two times per week for 3 months, combined with a mobile application (https://www.laxer.es). The assessments will be recorded at the beginning of the study, at postintervention and at the 6-month follow-up. The primary outcomes will be QoL, oral health, salivary secretion and salivary gland ultrasound. The pain pressure threshold, functional performance, mood and sleep quality will be secondary indicators. Ethics and dissemination: This study received ethics approval from the Andalusian Biomedical Research Ethics Portal (2402-N-21 CEIM/CEI Provincial de Granada) according to the Declaration of Helsinki for Biomedical Research. The results of this study will be presented at national and international conferences and published in peer-reviewed journals. Trial registration number: ClinicalTrials.gov NCT05106608.

21 November 2024 in BMJ Open Sport & Exercise Medicine
Verified
Journal Article
Open access
PDF file
Gavriella TsiarlestonGavriella Tsiarleston
Gavriella Tsiarleston
MLMaría Dolores López-Fernández
María Dolores López-Fernández
RPRodrigo Pavón-Muñoz
Rodrigo Pavón-Muñoz
IAIván Aguilera-García
Iván Aguilera-García
MLMaría López-Corchón
María López-Corchón
VSVíctor Segura-Jiménez
Víctor Segura-Jiménez
The HEALTHYBACK trial is based on a multimodal intervention to determine the effectiveness of a supervised physical exercise, mindfulness, behaviour change and pain neuroscience education programme on several health variables in individuals with chronic primary low back pain (CPLBP). The study will be a randomised controlled trial among 70 individuals diagnosed with CPLBP (aged 18–65 years). The intervention will be conducted in person within a hospital setting for 16 weeks and comprises a first phase (16 sessions supervised physical exercise (2 days/week, 45 min/session), mindfulness (1 day/week, 2.5 hours/session), behaviour change (daily/24 hours via a wrist-worn activity prompting device) and pain neuroscience education (1 day/biweekly, 2 hours/session)) and a second phase (16 sessions functional full-body muscle strengthening exercise, 3 days/week, 50 min/session). The primary outcomes will include perceived acute pain, pain pressure threshold, conditioned pain modulation, temporal summation of pain and disability due to pain. Secondary measures will include physical fitness, body composition, gait parameters, device-measured physical activity and sedentary behaviour, haematological profile, self-reported sedentary behaviour, quality of life, pain catastrophising, mental health, sleep duration and quality, and symptoms related to central sensitisation. The groups will undergo pretest (before the intervention), post-test (after each phase of the intervention) and retest (at a 6-week detraining period after the intervention) measurements. The results will determine the effectiveness of multidimensional interventions on several health parameters in individuals with CPLBP. They will provide knowledge for pain management and functioning in affected individuals, which might diminish the need for primary healthcare services. Trial registration number: NCT06114264.